t-sign-platform
(2)
Akamis Bio
Akamis Bio is a clinical-stage oncology company building intravenously delivered, tumor-targeted gene therapies on its Tumor-Specific Immuno-Gene (T-SIGn) platform. Using a replication-competent, directed-evolution-engineered group B adenovirus that selectively infects epithelial-derived solid tumors, Akamis turns cancer cells into local 'drug factories' that express immune-modulating payloads inside the tumor while sparing healthy tissue. Headquartered in Cambridge, Massachusetts (with UK roots as the former PsiOxus Therapeutics), its lead program NG-350A delivers a CD40 agonist antibody directly to primary and metastatic tumors.
Howard Davis
Howard Davis, Ph.D., is the CEO of Akamis Bio, a clinical-stage oncology company in Cambridge, Massachusetts building tumor gene therapies on its proprietary T-SIGn platform. A chemical engineer turned biomedical engineer, he spent two decades moving between Boston Consulting Group, Novartis, Biogen, Flagship Pioneering and Atlas Venture before taking the top job at the company once known as PsiOxus. His current mission: prove that an adenoviral therapy delivered through a vein - not a needle into the tumor - can reach metastatic cancer the body has hidden, and turn those tumors against themselves.